± HEALTH Objective To evaluate the accuracy, completeness, clarity, source transparency, and readability of leading AI…+ HEALTH Background Early prediction of in-hospital mortality in critically ill patients can aid clinicians in optimiz…+ HEALTH Hypertension is a major risk factor for cardiovascular diseases, with changes in gut microbiota composition a…+ SCIENCE Fire ants (Solenopsis spp. Westwood) pose a major ecological and economic threat, mainly due to the invasive…± HEALTH Objectives The current study aimed to quantify the diagnostic accuracy of commonly utilized chatbots includin…+ HEALTH Objective Despite elevated risk for epilepsy following traumatic brain injury (TBI), there are limited tools…± HEALTH Timely and accurate diagnosis of ST-elevation myocardial infarction (STEMI) is critical in military operation…+ HEALTH Colorectal cancer (CRC) exhibits substantial metabolic heterogeneity. This study developed a robust prognosti…
TruaceTracing the truth around AIWednesday, August 5, 2026
Subscribe
TRV-2026-0584Version 1 · Certified

Written 2026-07-29 06:08:52 UTC · current record

Reason for this version

Certified into the record

Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-0584
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-07-29T06:08:52.269989Z
status: published
lens: trace
sector: climate
headline: Global genomic surveillance of β-lactam resistance in Escherichia coli across human, animal, and environmental reservoirs
dek: Background Escherichia coli poses a global health threat from increasing β-lactam resistance. This study uses genomic and One-Health data to map resistance patterns and enhance antimicrobial resistance (AMR) prediction and management. Methods This study performed a One-Health whole-genome analysis of 30,554 E. coli isolates from human, animal, and environmental sources, spanning from 2000 to 2025. Publicly available genomic data were retrieved from NCBI, encompassing β-lactam resistance genes, including extended…
gain_title: Gradient-boosted machine learning predicted carbapenem MICs from resistance gene profiles with strong performance for imipenem and ertapenem, supporting AMR surveillance.
problem_title: The same gradient-boosted models showed poor agreement with observed MICs for ampicillin and piperacillin-tazobactam and struggled with beta-lactamase inhibitor combinations.
trace_subject: gradient-boosted machine learning prediction of beta-lactam MICs from E. coli genomic resistance profiles
gain_reading: Gradient-boosted machine learning predicted carbapenem MICs from resistance gene profiles with strong performance for imipenem and ertapenem, supporting AMR surveillance.
gain_evidence: gradient-boosted machine learning algorithms predicting minimum inhibitory concentrations (MICs) based on antibiotic resistance gene profiles and chromosomal features | Model performance was strongest for carbapenems, particularly imipenem (R 2 = 0.88) and ertapenem (R 2 = 0.74)
problem_reading: The same gradient-boosted models showed poor agreement with observed MICs for ampicillin and piperacillin-tazobactam and struggled with beta-lactamase inhibitor combinations.
problem_evidence: predictions for ampicillin and piperacillin-tazobactam showed poor agreement with observed MICs
quick_read: A One-Health study analyzed 30,554 E. coli whole-genome sequences from human, animal and environmental sources across 126 countries from 2000 to 2025, using AMRFinderPlus and MLST to map resistance genes and clones, and applied gradient-boosted machine learning to predict MICs from gene profiles and chromosomal features.

The work matters because it shows AI can accurately predict carbapenem resistance for surveillance, with imipenem R2 0.88, yet remains unreliable for ampicillin and inhibitor combinations, leaving uncertainty about clinical deployment across all beta-lactams and about generalizability beyond the curated NCBI dataset.
limitation: Model accuracy was uneven across drug classes, with strong results for carbapenems but poor agreement for ampicillin and beta-lactamase inhibitor combinations, limiting broad clinical use.
tag: Automated dual reading
key_points: Analysis covered 30,554 E. coli whole-genome sequences from 126 countries between 2000 and 2025, including 14,320 human, 8184 animal, and 3941 environmental isolates. | MLST identified dominant sequence types ST131, ST73 and ST1193 in human isolates, ST10 in animal isolates, and ST155 in environmental isolates. | Temporal analysis showed rising prevalence of bla CTX-M-15 , bla NDM-5 , and bla OXA-1 driving beta-lactam resistance in high-risk clones.
rundown: Researchers retrieved 30,554 E. coli genomes from NCBI spanning 2000 to 2025, with an average length of 5,120,983 bp, and curated beta-lactam resistance genes using AMRFinderPlus alongside MLST and pathotype assignment.

By publication date July 24 2026, the study reported observed model performance strongest for carbapenems and weakest for ampicillin and piperacillin-tazobactam, concluding that integrating genomics and One-Health data can guide AMR surveillance and control.
sources:
- peer_reviewed | Infection, Genetics and Evolution | https://doi.org/10.1016/j.meegid.2026.105998 | 2026-07-24
prev: 0000000000000000000000000000000000000000000000000000000000000000
sha256
7ef54e5d5a94d4d9aa15934a57cc4501c42c605622299c5483be742e3f4db1b5
previous
0000000000000000000000000000000000000000000000000000000000000000
Verify this record
How to verify without trusting this page

Fetch the canonical text of any version from /api/record/TRV-2026-0584 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.